SCHEMBL4341663

SCHEMBL4341663

Cc1cccc(C)c1NC(=O)Nc1ccc(O)cc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR1 P25024 1/20 0.59
CXCR2 P25025 1/20 0.51
LMNA P02545 2/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
ALOX15 P16050 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49
HSD17B10 Q99714 1/20 0.49
DDX3X O00571 1/20 0.47
POLB P06746 1/20 0.47
TRPV1 Q8NER1 3/20 0.47
DRD2 P14416 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2B P41595 1/20 0.46
PKM P14618 1/20 0.45
KDM4E B2RXH2 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
EPHX1 P07099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6566895 0.89 CXCR2 (0.66) CXCR1CXCR2LMNAKMT2AALDH1A1
SCHEMBL4347676 0.87 CXCR1 (0.68) CXCR1CXCR2LMNAKMT2AALDH1A1
SCHEMBL5595504 0.82 CXCR1 (0.66) CXCR1CXCR2LMNAKMT2AALDH1A1
SCHEMBL30051979 0.80 MAPT (0.67) LMNAKMT2AALDH1A1MAPTALOX15
SCHEMBL19427520 0.78 CXCR1 (0.63) CXCR1CXCR2KMT2AMAPTRAB9A
SCHEMBL13804532 0.78 CXCR1 (0.58) CXCR1CXCR2KMT2AALDH1A1MAPT
SCHEMBL4359936 0.77 KCNMA1 (0.62) LMNAKMT2AMAPTHTTPOLB
SCHEMBL5195764 0.77 KMT2A (0.64) CXCR2KMT2AALDH1A1MAPTHTT
SCHEMBL4351749 0.77 NPC1 (0.54) CXCR1CXCR2LMNAKMT2AALDH1A1
SCHEMBL4350075 0.77 CXCR2 (0.71) CXCR1CXCR2LMNAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 CXCR1 832/4885CXCR2 600/4885LMNA 3160/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 CXCR1 1199/4885CXCR2 688/4885LMNA 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.